Elixir Pharmaceuticals Announces Presentation of Data in Programs to Treat and Prevent Metabolic Diseases
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., today announced the presentation of preclinical data from the Company’s ghrelin antagonist program and its sirtuin program at Strategic Research Institute’s 6th Annual Metabolic Diseases Drug Discovery & Development World Summit, being held in La Jolla, California, July 16-17, 2007. According to Peter DiStefano, Ph.D., Chief Scientific Officer at Elixir, the Company’s ghrelin antagonist is the most advanced program of its kind and represents a potential treatment for a range of metabolic disorders. A naturally occurring hormone, ghrelin has been identified as having a key role in metabolism and energy storage. Elixir’s lead ghrelin antagonist, EX-1350, has demonstrated a variety of beneficial effects in preclinical studies, notably decreasing body weight, improvements in blood glucose and insulin levels, and reductions in fatty liver. Elixir intends to initiate a Phase 1 clinical trial of its ghrelin antagonist in 2008.